News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
482,989 Results
Type
Article (8052)
Company Profile (139)
Press Release (474894)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166786)
Career Advice (305)
Deals (25741)
Drug Delivery (7)
Drug Development (52918)
Employer Resources (14)
FDA (9765)
Job Trends (8575)
News (238277)
Policy (17917)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (478)
Accelerated approval (21)
ADA (18)
Adcomms (1)
Allergies (94)
Alliances (33166)
ALS (105)
Alzheimer's disease (969)
Antibody-drug conjugate (ADC) (251)
Approvals (10330)
Artificial intelligence (305)
ASCO (159)
Autoimmune disease (194)
Automation (27)
Bankruptcy (262)
Best Places to Work (6960)
BIO (36)
BIOSECURE Act (1)
Biosimilars (101)
Biotechnology (88)
Bladder cancer (132)
Brain cancer (27)
Breast cancer (496)
Cancer (3528)
Cardiovascular disease (210)
Career advice (245)
Career pathing (1)
CAR-T (166)
Celiac Disease (1)
Cell therapy (463)
Cervical cancer (34)
Clinical research (47729)
Collaboration (1192)
Compensation (1372)
Complete response letters (33)
COVID-19 (749)
CRISPR (62)
C-suite (694)
Cystic fibrosis (84)
Data (5471)
Denatured (4)
Depression (100)
Dermatology (58)
Diabetes (332)
Diagnostics (4133)
Digital health (36)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (142)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (157)
Earnings (72973)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87417)
Executive appointments (675)
FDA (12267)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (16)
Frontotemporal dementia (23)
Funding (885)
Gene editing (123)
Generative AI (9)
Gene therapy (309)
GLP-1 (283)
Government (940)
Grass and pollen (2)
Guidances (278)
Healthcare (9313)
Hematology (95)
HIV (49)
Huntington's disease (23)
IgA nephropathy (60)
Immunology and inflammation (95)
Immuno-oncology (53)
Indications (148)
Infectious disease (934)
Inflammatory bowel disease (124)
Inflation Reduction Act (4)
Influenza (83)
Intellectual property (244)
Interviews (41)
IPO (12379)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (14)
Layoffs (59)
Legal (5196)
Liver cancer (43)
Longevity (15)
Lung cancer (485)
Lymphoma (239)
Machine learning (27)
Management (3)
Manufacturing (505)
Marketing (6)
MASH (115)
Medical device (8631)
Medtech (8744)
Mergers & acquisitions (14345)
Metabolic disorders (684)
mRNA (49)
Multiple sclerosis (103)
NASH (4)
Neurodegenerative disease (216)
Neuropsychiatric disorders (38)
Neuroscience (1791)
NextGen: Class of 2026 (3151)
Non-profit (842)
Obesity (218)
Opinion (11)
Ovarian cancer (154)
Pain (166)
Pancreatic cancer (189)
Parkinson's disease (196)
Partnered (11)
Patents (456)
Patient recruitment (469)
Peanut (31)
People (41113)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15435)
Phase 2 (21302)
Phase 3 (14353)
Pipeline (6573)
Policy (17)
Postmarket research (1571)
Preclinical (6534)
Press Release (34)
Prostate cancer (185)
Psychedelics (7)
Radiopharmaceuticals (186)
Rare diseases (551)
Real estate (3017)
Recruiting (6)
Regulatory (14656)
Reports (16)
Research institute (581)
Resumes & cover letters (45)
Rett syndrome (39)
RNA editing (5)
RSV (47)
Schizophrenia (98)
Series A (147)
Series B (116)
Service/supplier (4)
Sickle cell disease (61)
Spinal muscular atrophy (87)
Sponsored (5)
Startups (2018)
Stomach cancer (3)
Supply chain (47)
Vaccines (308)
Venture capital (17)
Weight loss (69)
Women's health (73)
Date
Today (62)
Last 7 days (252)
Last 30 days (1122)
Last 365 days (19132)
2026 (10429)
2025 (19270)
2024 (22999)
2023 (26556)
2022 (34608)
2021 (37185)
2020 (33487)
2019 (23270)
2018 (17478)
2017 (18787)
2016 (17930)
2015 (24272)
2014 (21692)
2013 (18139)
2012 (20225)
2011 (20450)
2010 (20335)
Location
Africa (227)
Alabama (68)
Alaska (2)
Arizona (287)
Arkansas (11)
Asia (17828)
Australia (2095)
California (11421)
Canada (3030)
China (496)
Colorado (461)
Connecticut (387)
Delaware (200)
Europe (24613)
Florida (1702)
Georgia (360)
Hawaii (2)
Idaho (46)
Illinois (672)
India (40)
Indiana (306)
Iowa (13)
Japan (384)
Kansas (97)
Kentucky (30)
Louisiana (24)
Maine (29)
Maryland (1143)
Massachusetts (7536)
Michigan (298)
Minnesota (531)
Mississippi (4)
Missouri (76)
Montana (20)
Nebraska (11)
Nevada (112)
New Hampshire (60)
New Jersey (2519)
New Mexico (11)
New York (2718)
North Carolina (1220)
North Dakota (4)
Northern California (5677)
Ohio (263)
Oklahoma (14)
Oregon (14)
Pennsylvania (2182)
Puerto Rico (20)
Rhode Island (29)
South America (405)
South Carolina (75)
South Dakota (1)
Southern California (4736)
Tennessee (112)
Texas (1841)
United States (37200)
Utah (340)
Vermont (1)
Virginia (145)
Washington D.C. (38)
Washington State (885)
West Virginia (1)
Wisconsin (71)
482,989 Results for "embera neurotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
May 4, 2026
·
5 min read
Press Releases
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.
May 12, 2026
·
4 min read
Press Releases
Revalesio to Present Advances in Stroke Treatment with RNS60 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
March 5, 2026
·
5 min read
Drug Development
Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2a Study of EMB-001 in Smoking Cessation
Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2a Study of EMB-001 in Smoking Cessation
June 30, 2021
·
5 min read
Press Releases
Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics
May 27, 2025
·
7 min read
Drug Development
Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2 Study of EMB-001 in Cocaine Use Disorder
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine and potentially other addictions, today announced that the first subjects have begun dosing of EMB-001 in a Phase 2 study for cocaine use disorder.
August 31, 2020
·
4 min read
Press Releases
Stream Biomedical, Inc. Announces Acceptance of Abstract for Presentation at Annual Meeting of the American Society of Neurotherapeutics (ASENT) Conference 2025
March 5, 2025
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
Avenue Therapeutics, Inc. today announced that Amy Chappell, M.D., FAAN will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell’s Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of epilepsy at the American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting on Wednesday, March 13, 2024.
March 11, 2024
·
6 min read
Drug Development
Embera NeuroTherapeutics Completes Series B Financing and Receives Grants to Advance EMB-001 into Phase 2 Clinical Studies in Cocaine Use Disorder and Smoking Cessation
Embera appoints Bruce McCarthy, M.D. as Chief Medical Officer Gary Connor, RN promoted to Chief Operating Officer
December 19, 2019
·
4 min read
1 of 48,299
Next
